Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
; k! K1 A O- a9 O2 J
- R+ D" I8 ^6 Q) \1 c# M0 V5 L
# ?; E/ P, [: [$ B2 B& `Sub-category:
" T- x- v4 X1 x3 Q" e( ^0 N/ rMolecular Targets 0 [- p# r) H0 J) N
7 p! n6 T. R" [# S1 d: T8 `: U) ?# y0 _/ k8 Z2 C
Category:* C* [! m- O. p; {* l
Tumor Biology $ o/ Z" j/ v0 [2 ~
* h7 ? E) l( ^5 z4 [
% ^, n' x+ Z! xMeeting:
z$ [% p& N; s4 c y! ^' X2011 ASCO Annual Meeting
& l0 z, L5 }0 R# M& b. X( [3 b. o k5 x% q. e
# V" B8 @3 t0 j% B" X4 D' B8 RSession Type and Session Title:' d6 e9 f" b$ X' V( b: |
Poster Discussion Session, Tumor Biology - F, N# {) i' G( Q: P
( ~9 k" ?1 T+ ~) o
+ n7 }( y/ l; @$ ]0 v
Abstract No:
1 R4 d% m8 o4 Y: `7 |/ @10517
, d x I+ H; o# L8 E
" d: ?6 s* M) @. Z% C6 E G+ X! W/ ^! @' c# I" X' j
Citation:
* a5 G6 A! ^) FJ Clin Oncol 29: 2011 (suppl; abstr 10517)
9 ]& Z$ w7 @8 U1 n5 S2 h8 I* g: z9 z9 ?- I7 h3 L4 [6 e: h
% {: D5 U. k' P& Z5 U3 E WAuthor(s):/ Z* }/ c" p/ I; M% o
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
" r; t* g) v8 `" }* D6 [
5 E4 ~2 Q/ w# d, o5 ]1 x$ P
9 ^3 { j1 Q! @* b {
7 P$ o( ~6 i @: v+ mAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ L4 f+ {" j& Q' v/ }5 Z, B- X1 c5 V( W; {( g' W
Abstract Disclosures
6 D- i- r. R1 `) W
, Y0 V0 Q! X3 ]+ Y* fAbstract:
. x3 L3 n0 i/ m! U8 r; n( ^+ h, o4 U4 |( F/ q
, C: [7 Q: a7 `! _7 ^. J/ uBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; d5 P& t) S7 u' C
' @! \. `$ [. Z- x/ j# N7 b! P
+ ~8 z" q1 p+ i: T9 `) n; p |
% n( |1 s8 i; f$ O/ l
显身卡
